Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 15 articles:
HTML format



Single Articles


    September 2021
  1. FELIP E, Altorki N, Zhou C, Csoszi T, et al
    Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
    Lancet. 2021 Sep 17. pii: S0140-6736(21)02098.
    PubMed     Abstract available


  2. GAINOR JF
    Adjuvant PD-L1 blockade in non-small-cell lung cancer.
    Lancet. 2021 Sep 17. pii: S0140-6736(21)02100.
    PubMed    


    July 2021
  3. BAAS P, Scherpereel A, Nowak AK, Oukessou A, et al
    Heterogeneity of treatment effects in malignant pleural mesothelioma - Authors' reply.
    Lancet. 2021;398:302.
    PubMed    


  4. DI MAIO M, Tagliamento M
    Heterogeneity of treatment effects in malignant pleural mesothelioma.
    Lancet. 2021;398:301-302.
    PubMed    


  5. THAI AA, Solomon BJ, Sequist LV, Gainor JF, et al
    Lung cancer.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)00312.
    PubMed     Abstract available


    March 2021
  6. KHO SS, Ho YF, Chan SK, Tie ST, et al
    Mediastinal melioidosis masquerading as malignancy of the lung.
    Lancet. 2021;397:e8.
    PubMed    


    February 2021
  7. SEZER A, Kilickap S, Gumus M, Bondarenko I, et al
    Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
    Lancet. 2021;397:592-604.
    PubMed     Abstract available


  8. ROSELL R, Gonzalez-Cao M
    Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer.
    Lancet. 2021;397:557-559.
    PubMed    


    January 2021
  9. CERESOLI GL, Pasello G
    Immune checkpoint inhibitors in mesothelioma: a turning point.
    Lancet. 2021;397:348-349.
    PubMed    


  10. BAAS P, Scherpereel A, Nowak AK, Fujimoto N, et al
    First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
    Lancet. 2021;397:375-386.
    PubMed     Abstract available


  11. TREASURE T, Macbeth F, Farewell V, Williams NR, et al
    The fallacy of large survival gains from lung metastasectomy in colorectal cancer.
    Lancet. 2021;397:97-98.
    PubMed    


    August 2020
  12. SZTURZ P, Vermorken JB
    Further clinical interpretation and implications of KEYNOTE-048 findings.
    Lancet. 2020;396:379.
    PubMed    


  13. MCCAW ZR, Ludmir EB, Kim DH, Wei LJ, et al
    Further clinical interpretation and implications of KEYNOTE-048 findings.
    Lancet. 2020;396:378-379.
    PubMed    


  14. REVANNASIDDAIAH S, Devadas SK, Maka VV, Kilara N, et al
    Further clinical interpretation and implications of KEYNOTE-048 findings.
    Lancet. 2020;396:378.
    PubMed    


    May 2020
  15. HARRIS DA, Willis J, Tomann M
    A new era of coal workers' pneumoconiosis: decades in mines may not be required.
    Lancet. 2020;395:e82.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: